Pharmafile Logo
Pharmafocus logo
Advanced Search

Daxas

Showing 11 posts of 11 posts found.

NICE recommends AstraZeneca lung treatment

July 3, 2017
Sales and Marketing AstraZeneca, Daxas, NICE

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) it has emerged, …

News

NICE turns down AZ’s chronic obstructive pulmonary disease drug

February 13, 2017
Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease

AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …

News

Boehringer’s COPD drug passes hurdle

May 23, 2012
Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol

Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial.  The manufacturer wants the …

News
daxas_web

NICE rejects Merck’s COPD drug Daxas

December 9, 2011
Sales and Marketing COPD, Daxas, Merck, Nycomed

NICE has not recommended Merck’s COPD drug Daxas and is asking for a new clinical trial to test its effectiveness. …

News
Merck & Co

Merck’s COPD drug rejected by NICE

September 15, 2011
Sales and Marketing Daxas, MSD, Merck & Co, NICE, roflumilast

NICE has not recommended Merck Co’s Daxas and has advised the firm to conduct a clinical trial in order to …

News

Forest’s COPD drug approved in US

March 3, 2011
Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast

Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …

News

Nycomed’s Q3 undermined by pantoprazole decline

November 11, 2010
Sales and Marketing Daxas, Guangdong Techpool Bio-Pharma, Nycomed, Protium, pantoprazole

Nycomed has seen its sales inch downwards in the third quarter, as the decline of its biggest seller pantoprazole continued. …

News
GSK’s Seretide/Advair

New COPD and asthma treatments jostle for market space

October 6, 2010
Research and Development, Sales and Marketing COPD, Daxas, Onbrez Breezhaler, Revolair, asthma

Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …

Feature

Nycomed partners with Merck on Daxas

April 26, 2010
Sales and Marketing Daxas, Merck & Co, Nycomed

Swiss firm Nycomed and Merck & Co have agreed to co-promote oral chronic obstructive pulmonary disease candidate Daxas in Europe. …

News

Nycomed earmarks $96m for Russian manufacturing

September 24, 2009
Manufacturing and Production Daxas, Nycomed, Russia

Swiss drugmaker Nycomed has provided more details of its plan to build a large-scale production facility in Russia.In July, Nycomed …

News

Pfizer pulls out of Daxas collaboration

July 7, 2005
Sales and Marketing Daxas, Nycomed, Pfizer

Pfizer has pulled out of an agreement with Altana Pharma to develop and market a new treatment for asthma and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025